Intellia Therapeutics (NTLA) Competitors $8.87 +0.67 (+8.17%) Closing price 04/30/2025 04:00 PM EasternExtended Trading$8.92 +0.05 (+0.57%) As of 08:57 AM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more. Add Compare Share Share Competitors Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestSustainabilityTrendsBuy This Stock NTLA vs. ZLAB, AKRO, MRUS, MOR, SRRK, CRNX, PTGX, SWTX, OGN, and CPRXShould you be buying Intellia Therapeutics stock or one of its competitors? The main competitors of Intellia Therapeutics include Zai Lab (ZLAB), Akero Therapeutics (AKRO), Merus (MRUS), MorphoSys (MOR), Scholar Rock (SRRK), Crinetics Pharmaceuticals (CRNX), Protagonist Therapeutics (PTGX), SpringWorks Therapeutics (SWTX), Organon & Co. (OGN), and Catalyst Pharmaceuticals (CPRX). These companies are all part of the "pharmaceutical products" industry. Intellia Therapeutics vs. Zai Lab Akero Therapeutics Merus MorphoSys Scholar Rock Crinetics Pharmaceuticals Protagonist Therapeutics SpringWorks Therapeutics Organon & Co. Catalyst Pharmaceuticals Intellia Therapeutics (NASDAQ:NTLA) and Zai Lab (NASDAQ:ZLAB) are both medical companies, but which is the superior investment? We will contrast the two companies based on the strength of their profitability, dividends, institutional ownership, earnings, analyst recommendations, risk, valuation, community ranking and media sentiment. Does the MarketBeat Community prefer NTLA or ZLAB? Intellia Therapeutics received 213 more outperform votes than Zai Lab when rated by MarketBeat users. Likewise, 68.94% of users gave Intellia Therapeutics an outperform vote while only 64.53% of users gave Zai Lab an outperform vote. CompanyUnderperformOutperformIntellia TherapeuticsOutperform Votes44468.94% Underperform Votes20031.06% Zai LabOutperform Votes23164.53% Underperform Votes12735.47% Does the media favor NTLA or ZLAB? In the previous week, Zai Lab had 2 more articles in the media than Intellia Therapeutics. MarketBeat recorded 13 mentions for Zai Lab and 11 mentions for Intellia Therapeutics. Intellia Therapeutics' average media sentiment score of 1.10 beat Zai Lab's score of 0.79 indicating that Intellia Therapeutics is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Intellia Therapeutics 6 Very Positive mention(s) 0 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Zai Lab 6 Very Positive mention(s) 0 Positive mention(s) 2 Neutral mention(s) 1 Negative mention(s) 0 Very Negative mention(s) Positive Do insiders & institutionals have more ownership in NTLA or ZLAB? 88.8% of Intellia Therapeutics shares are owned by institutional investors. Comparatively, 41.7% of Zai Lab shares are owned by institutional investors. 3.2% of Intellia Therapeutics shares are owned by insiders. Comparatively, 13.9% of Zai Lab shares are owned by insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a stock is poised for long-term growth. Do analysts rate NTLA or ZLAB? Intellia Therapeutics currently has a consensus price target of $36.68, suggesting a potential upside of 313.58%. Zai Lab has a consensus price target of $47.37, suggesting a potential upside of 49.47%. Given Intellia Therapeutics' higher probable upside, equities analysts clearly believe Intellia Therapeutics is more favorable than Zai Lab.Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Intellia Therapeutics 1 Sell rating(s) 6 Hold rating(s) 12 Buy rating(s) 1 Strong Buy rating(s) 2.65Zai Lab 0 Sell rating(s) 1 Hold rating(s) 3 Buy rating(s) 0 Strong Buy rating(s) 2.75 Is NTLA or ZLAB more profitable? Intellia Therapeutics has a net margin of 0.00% compared to Zai Lab's net margin of -76.14%. Zai Lab's return on equity of -36.97% beat Intellia Therapeutics' return on equity.Company Net Margins Return on Equity Return on Assets Intellia TherapeuticsN/A -49.34% -40.27% Zai Lab -76.14%-36.97%-27.10% Which has more risk & volatility, NTLA or ZLAB? Intellia Therapeutics has a beta of 2.23, indicating that its stock price is 123% more volatile than the S&P 500. Comparatively, Zai Lab has a beta of 1.09, indicating that its stock price is 9% more volatile than the S&P 500. Which has higher valuation and earnings, NTLA or ZLAB? Zai Lab has higher revenue and earnings than Intellia Therapeutics. Zai Lab is trading at a lower price-to-earnings ratio than Intellia Therapeutics, indicating that it is currently the more affordable of the two stocks. CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings RatioIntellia Therapeutics$57.88M15.86-$481.19M-$5.25-1.69Zai Lab$398.99M8.75-$334.62M-$2.59-12.24 SummaryIntellia Therapeutics beats Zai Lab on 11 of the 19 factors compared between the two stocks. Get Intellia Therapeutics News Delivered to You Automatically Sign up to receive the latest news and ratings for NTLA and its competitors with MarketBeat's FREE daily newsletter. Email Address New MarketBeat Followers Over TimeWhat are MarkeBeat Followers?This chart shows the number of new MarketBeat users adding {thisCompany.Symbol} and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period. Skip ChartMedia Sentiment Over TimeWhat is Media Sentiment?This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.Skip Chart NTLA vs. The Competition Export to ExcelMetricIntellia TherapeuticsDiagnostic substances IndustryMedical SectorNASDAQ ExchangeMarket Cap$918.20M$2.35B$5.57B$7.83BDividend YieldN/A0.75%5.11%4.22%P/E Ratio-1.636.4322.4418.48Price / Sales15.8650.54394.09103.59Price / CashN/A15.7538.1834.62Price / Book0.763.646.774.25Net Income-$481.19M-$65.73M$3.22B$248.23M7 Day Performance8.44%1.10%1.49%0.89%1 Month Performance33.18%-1.61%4.00%3.53%1 Year Performance-60.58%-10.81%16.21%5.08% Intellia Therapeutics Competitors List Export to ExcelCompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)NTLAIntellia Therapeutics4.4678 of 5 stars$8.87+8.2%$36.68+313.6%-58.6%$918.20M$57.88M-1.63600Upcoming EarningsPositive NewsZLABZai Lab2.173 of 5 stars$29.46+2.1%$47.37+60.8%+100.6%$3.23B$398.99M-10.641,950Upcoming EarningsPositive NewsAKROAkero Therapeutics3.7943 of 5 stars$37.81+0.5%$76.29+101.8%+129.3%$3.01BN/A-10.0830Insider TradeNews CoveragePositive NewsMRUSMerus3.4294 of 5 stars$43.53+1.1%$85.31+96.0%+1.3%$3.01B$36.13M-11.0237Upcoming EarningsAnalyst ForecastShort Interest ↓Analyst RevisionNews CoveragePositive NewsMORMorphoSysN/A$18.96flatN/AN/A$2.86B$238.28M-5.45730SRRKScholar Rock4.0568 of 5 stars$30.04-2.3%$42.67+42.0%+124.3%$2.85B$33.19M-12.78140Upcoming EarningsInsider TradeNews CoveragePositive NewsCRNXCrinetics Pharmaceuticals3.6693 of 5 stars$30.24-0.6%$73.00+141.4%-23.8%$2.81B$1.04M-8.11210Upcoming EarningsNews CoveragePositive NewsPTGXProtagonist Therapeutics3.4338 of 5 stars$45.80-1.0%$65.44+42.9%+82.5%$2.81B$434.43M17.22120Upcoming EarningsNews CoveragePositive NewsSWTXSpringWorks Therapeutics1.9424 of 5 stars$37.06-2.3%$73.20+97.5%-0.8%$2.78B$191.59M-10.65230Analyst ForecastNews CoverageOGNOrganon & Co.4.7614 of 5 stars$10.53-5.3%$20.60+95.6%-30.5%$2.72B$6.40B3.1610,000Positive NewsCPRXCatalyst Pharmaceuticals4.6886 of 5 stars$22.03-2.2%$32.29+46.6%+61.4%$2.69B$491.73M18.6780Upcoming EarningsNews CoveragePositive News Related Companies and Tools Related Companies Zai Lab Alternatives Akero Therapeutics Alternatives Merus Alternatives MorphoSys Alternatives Scholar Rock Alternatives Crinetics Pharmaceuticals Alternatives Protagonist Therapeutics Alternatives SpringWorks Therapeutics Alternatives Organon & Co. Alternatives Catalyst Pharmaceuticals Alternatives Top 10 Stock Comparisons Semiconductor Stocks Artificial Intelligence Stocks Growth Stocks Magnificent Seven Stocks Pharmaceutical Stocks Ecommerce Stocks Bitcoin Stocks Meme Stocks Cryptocurrency Stocks Cybersecurity Stocks This page (NASDAQ:NTLA) was last updated on 5/1/2025 by MarketBeat.com Staff From Our PartnersHow to invest in Elon Musk’s Optimus before its launchElon Musk is set to completely take over the AI industry with Optimus… A breakthrough AI-powered robot that El...InvestorPlace | SponsoredIs he more powerful than Trump? Is there anybody more powerful than Donald Trump right now? In a single tariff announcement, he wiped out n...Porter & Company | Sponsored[Action Required] Claim Your FREE IRS Loophole GuideThis shouldn't surprise anyone who's been paying attention, but... Pres. Trump may be about to unleash the ...Colonial Metals | SponsoredTrump and Buffett Are Quietly Leading America’s Gold RevivalThe “Buffett Indicator” Predicts Gold Set To Dominate for Next Decade Each time the Buffett Indicator has...Golden Portfolio | SponsoredJames Altucher: Do not invest in AI unless…I made millions during the crypto boom. Many “experts” are now saying… Artificial Intelligence opportuni...Paradigm Press | SponsoredThis isn’t a trade war. It’s worse…Investigative Journalist Bombhsell: The Curse on the U.S Dollar Depleted retirement accounts? Meme coin inv...Stansberry Research | SponsoredElon Musk’s next move from the Oval Office?No one is closer to President Trump than Tesla CEO Elon Musk. He's been dubbed Trump's "first buddy." Tr...Weiss Ratings | SponsoredChina’s next move could destroy U.S. techThe U.S. fired the first shot with 145% tariffs. Apple relies heavily on Chinese production. Tesla needs Ch...Investors Alley | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Intellia Therapeutics, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Intellia Therapeutics With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
Buy NTLA Stock Free NTLA Stock Alerts